SBRT for Oligometastatic Castration-Refractory Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

89 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2022-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions. Patients with \<=3 metastatic lesions will receive stereotactic body radiotherapy (SBRT) as definitive treatment. Blood draws will be taken to monitor the development of anti-prostate cancer immunity

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer

NCT02192788

Oligometastatic Prostate Cancer

COMPLETED NA

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

NCT06205316

Biochemically Recurrent Prostate Carcinoma Oligometastatic Prostate Carcinoma Recurrent Prostate Adenocarcinoma +4 more

RECRUITING PHASE3

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

NCT03159676

Prostate Cancer

ACTIVE_NOT_RECRUITING

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT00547339

Prostate Cancer

COMPLETED PHASE1/PHASE2

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

NCT01540994

Prostatic Neoplasm

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SBRT for oligometastatic prostate cancer

SBRT

Intervention Type RADIATION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SBRT

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stereotactic ablative radiotherapy (SABR)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must be receiving standard of care SBRT as outlined in the Universal Content Management (UCM) Procedure Manual (http://mayocontent.mayo.edu/radoncology/categories/index.html)
* Age ≥ 18 years.
* Metastatic castration-refractory prostate cancer patients with ≤ 3 lesions identified on standard imaging and/or choline PET/CT within 60 days of registration
* Castrate levels of testosterone
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 (Appendix I).
* Life expectancy \> 6 months

Exclusion Criteria

Emergent cord compression for spinal metastases

* Severe, active co-morbidity, defined as follows:

1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration
2. Transmural myocardial infarction within the last 6 months prior to registration
3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
5. Severe hepatic disease, defined as a diagnosis of Child-Pugh Class B or C hepatic disease.
6. HIV positive with Cluster Differentiation 4 (CD4) count \< 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol.
7. End-stage renal disease (i.e., on dialysis or dialysis has been recommended).
* Metastases located within 3 cm of the previously irradiated structures:

1. Spinal cord previously irradiated to \> 40 Gy
2. Brachial plexus previously irradiated to \> 50 Gy
3. Small intestine, large intestine, or stomach previously irradiated to \> 45 Gy
4. Brainstem previously irradiated to \> 50 Gy
5. Lung previously irradiated with prior V20Gy \> 30%

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No